|
Apr 6
|
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|
|
Apr 4
|
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
|
|
Apr 3
|
Why Amarin Stock Was Rocketing Higher on Wednesday
|
|
Apr 3
|
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
|
|
Mar 25
|
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
|
|
Mar 5
|
Amarin Full Year 2023 Earnings: Beats Expectations
|
|
Mar 2
|
Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their Forecasts
|
|
Mar 1
|
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
|
|
Mar 1
|
Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call Transcript
|
|
Feb 29
|
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
|
|
Feb 29
|
Amarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic Competition
|
|
Feb 29
|
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Jan 12
|
Are Medical Stocks Lagging Amarin (AMRN) This Year?
|
|
Jan 11
|
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
|
|
Jan 11
|
Why Amarin Stock Skyrocketed Today
|
|
Jan 10
|
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
|
|
Dec 27
|
13 Most Promising Small-Cap Stocks According to Analysts
|
|
Dec 11
|
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 8
|
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
|
|
Dec 5
|
What Makes Amarin (AMRN) a New Buy Stock
|